Ostwal V, Basu S, Bhargava P, et al. - Researchers undertook this retrospective study to assess the activity of CAPTEM (capecitabine-temozolomide) in patients suffering from grade 2 and grade 3 neuroendocrine neoplasms (NENs), as well as to explore prognostic factors. This study involved 68 patients treated with CAPTEM; of these, 29 patients (43%) received CAPTEM alone and 39 patients (57%) underwent concurrent peptide receptor radionuclide therapy (PRRT). Good tolerability was seen with both regimens. In grade 2 and grade 3 NENs with dual SSTR and 18FDG expression, study findings demonstrated significant activity with CAPTEM, alone or concurrent with PRRT. A strong predictor for inferior outcomes was a Ki67 index >5%; this should be investigated further as a prognostic cut-off in grade 2 NENs. In this group of tumors with significant baseline 18FDG expression, early initiation of CAPTEM should be considered.